Study | Reason for exclusion |
---|---|
Anonymous 1994 | Allocation: not randomised ‐ review. |
Axelson 1996 | Allocation: not randomised. Interventions: risperidone vs risperidone + other antipsychotic drugs. |
Barak 2000 | Allocation: randomised. Participants: DSM‐IV schizophrenia. Interventions: risperidone vs typical neuroleptics. Outcomes: information taken from conference abstract, all data unusable, further information being sought. |
Berman 1995 | Allocation: randomised. Participants: DSM‐III‐R schizophrenia. Interventions: risperidone vs haloperidol. Outcomes: information taken from conference abstract, all data unusable as numbers randomised to each group not given, further information being sought. |
Bilder 2001 | Allocation: randomised. Participants: treatment resistant DSM‐IV schizophrenia or schizoaffective disorder. Interventions: risperidone vs haloperidol, olanzapine or clozapine. Outcomes: information taken from conference poster, all data unusable as numbers randomised to each group not given, further information being sought. |
Bondolfi 1996 | Allocation: randomised. Participants: treatment resistant schizophrenia. Interventions: risperidone vs clozapine, atypical comparison. |
Brecher 1998 | Allocation: randomised. Blindness: double. Participants: schizophrenia, schizoaffective disorder. Interventions: risperidone vs olanzapine, atypcial comparison. |
Carman 1995 | Allocation: not randomised ‐ review. |
Ceskova 1994 | Allocation: randomised. Participants: ICD‐10 schizophrenia or schizoaffective psychoses. Interventions: risperidone vs perphenazine. Outcomes: all data unusable as no individual group data given. |
Cetin 1999 | Allocation: randomised. Participants: schizophrenia. Interventions: risperidone vs haloperidol. Outcomes: no usable data, data taken from conference abstract, further information being sought. |
Czober 1993 | Allocation: not randomised. |
Daniel 1996 | Allocation: randomised. Participants: schizophrenia/schizoaffective disorder. Interventions: risperidone vs clozapine, atypical comparison. |
Deshmukh 1998 | Allocation: unclear if randomised, seeking further information. |
Estrella 1996 | Allocation: randomised. Participants: treatment resistant schizophrenia. Interventions: risperidone vs clozapine, atypical comaprison. |
Gallhofer 1995 | Allocation: randomised. Participants: schizophrenia. Interventions: risperidone vs conventional neruoleptics. Outcomes: no usable data, information available in conference abstract only, further information being sought. |
Gelders 1989 | Allocation: not randomised, review. |
Gureje 1998 | Allocation: randomised. Blindness: double. Participants: schizophrenia, schizophreniform disorder, schizoaffective disorder. Interventions: risperidone vs olanzapine, atypical comparison. |
Heinrich 1994 | Allocation: randomised. Participants: schizophrenia. Interventions: risperidone vs clozapine, atypical comparison. |
Heylen 1992 | Allocation: not randomised, review. |
Kleiser 1995 | Allocation: randomised. Participants: chronic schizophrenia. Interventions: risperidone vs clozapine, atypical comparison. |
Klieser 1996 | Allocation: not randomised, review. |
Kopala 1996 | Allocation: not randomised, review. |
Meltzer 1996 | Allocation: randomised. Participants: schizophrenia. Interventions: clozapine withdrawl vs typical neuroleptic. |
Muller 1998 | Allocation: randomised. Participants: schizophrenia, schizoaffective, major depression with psychotic features. Interventions: risperidone vs haloperidol. Outcomes: unable to use data from those with schizophrenia or schizoaffective disorder alone, further information being sought. |
Murasaki 1995 | Allocation: unclear if randomised, seeking further information. |
Nagao 1998 | Allocation: unclear if randomised. Participants: people with DSM‐IV schizophrenia. Interventions: risperidone vs haloperidol, cross‐over. Outcomes: no relevant or usuable outcomes, further information being sought. |
Pathiraja 1995 | Allocation: randomised. Participants: DSM‐II‐R schizophrenia. Interventions: risperidone vs haloperidol, MAR 327 or placebo. Outcomes: unusable data, information taken from conference abstract, further information being sought. |
Sikich 2001 | Allocation: randomised. Participants: DSM‐VI psychotic disorder. Interventions: risperidone vs haloperidol or olanzapine. Outcomes: all data unusable, information taken from conference abstract, further information being sought. |
Zhou 1998 | Allocation: randomised. Participants: chronic schizophrnenia. Interventions: risperidone vs haloperidol. Outcomes: all data unusable, information taken from english abstract, further information and translation being sought. |
Zinner 1992 | Allocation: unclear if randomised. Participants: people with chronic DSM‐III‐R schizophrenia. Interventions: risperidone vs haloperidol. Outcomes: all data unusable, information taken from conference abstract, further information being sought. |
DSM ‐ Diagnostic Statistical Manual (versions II to IV, R=revised)